Sanjivani Paranteral Q4 Revenue Down 42.2% YoY

• Investor presentation discloses Q4 FY26 standalone revenue of ₹105.1 mn, down 42.2% year-over-year.
• Standalone PAT declined 57.2% YoY to ₹9.4 mn with EBITDA down 45.6% to ₹16.6 mn for Q4 FY26.
• Full-year FY26 revenue decreased 7.6% to ₹647.6 mn while PAT improved 14.6% to ₹69.2 mn annually.
• Company operates in pharmaceutical CDMO with manufacturing facilities in Navi Mumbai, Dehradun, and international presence.